SYNERGY-NASH: Tirzepatide's Liver Disease Breakthrough

SYNERGY-NASH showed tirzepatide produced MASH resolution in up to 62% of patients. Here's the trial design, results, and what it means for liver disease therapy.

SYNERGY-NASH tested tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) — a progressive liver disease driven by metabolic dysfunction and obesity that has been a major unmet therapeutic need. The trial produced some of the strongest evidence yet that GLP-1/GIP dual agonism can produce meaningful improvements in liver histology and fibrosis.

Published in late 2024, SYNERGY-NASH showed that tirzepatide at multiple doses produced MASH resolution without fibrosis worsening in a substantially higher proportion of patients than placebo, with a dose-response relationship. The findings have reshaped the clinical view of what metabolic therapies can achieve in liver disease.

Trial Design

SYNERGY-NASH enrolled 190 adults with biopsy-confirmed MASH (NAS ≥4 with ≥1 in each component) and moderate to advanced fibrosis (F2-F3). Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 52 weeks. The primary endpoint was MASH resolution without worsening of fibrosis on end-of-treatment biopsy. Secondary endpoints included fibrosis improvement without MASH worsening, changes in imaging markers (MRI-PDFF for liver fat, MRE for stiffness), and biomarker changes.

Primary Results

The dose-response relationship was clean, with each dose step showing incrementally higher proportions of histologic resolution. The placebo rate of approximately 10% is consistent with spontaneous MASH resolution observed in the natural history of the disease.

Fibrosis Improvement

The secondary endpoint of fibrosis improvement without MASH worsening is arguably more important clinically than MASH resolution alone, since fibrosis is the strongest predictor of long-term liver outcomes. SYNERGY-NASH showed dose-dependent improvement in fibrosis scores, with the top dose producing fibrosis improvement in approximately 50% of patients versus 30% on placebo. This is a meaningful effect in a disease where fibrosis improvement has been historically difficult to achieve with pharmacologic intervention.

Imaging and Biomarker Outcomes

Liver fat quantified by MRI-PDFF decreased substantially in the tirzepatide arms — typically 40-60% reduction from baseline — compared to minimal change on placebo. Liver stiffness by MRE improved. Serum ALT, AST, and other biochemical markers of liver injury decreased significantly. Weight loss paralleled the histologic and biomarker improvements, though statistical analyses suggested the liver effects were only partially mediated by weight change, consistent with direct metabolic mechanisms.

Safety Profile

Adverse events were consistent with the established tirzepatide safety profile: gastrointestinal effects most common, generally mild to moderate, with rates correlating to dose. No unexpected hepatotoxicity signals emerged, which is important because some earlier anti-MASH candidates had liver safety concerns. Discontinuation rates were higher at the top dose but acceptable given the magnitude of histologic benefit.

The Regulatory and Clinical Implications

SYNERGY-NASH was a proof-of-concept phase 2 trial, not a registration trial. Eli Lilly has indicated plans for larger phase 3 programs to support regulatory submission for MASH. Given the magnitude of effect and the dose-response, the probability of successful registration trials appears high, though phase 3 MASH trials have historically been difficult due to endpoint variability and population heterogeneity.

For the broader GLP-1 kidney-and-liver evidence context, see our FLOW trial review and retatrutide phase 2 review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.